Pegylated erythropoietin - 3SBioAlternative Names: PEG EPO- 3SBio
Latest Information Update: 22 Jan 2016
At a glance
- Originator Sciprogen
- Developer 3SBio
- Class Erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anaemia
Most Recent Events
- 22 Jan 2016 Preclinical trials in Anaemia in China (Parenteral)